Overview

Ga-68 MAA Distribution in PAE Patients

Status:
Withdrawn
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Purpose: The purpose of this study is to evaluate Ga-68 MAA distribution on PET/MRI after injection into the prostatic arteries in patients without prostate cancer who are being treated with prostate artery embolization for benign prostatic hyperplasia. Participants: Study subjects will be 5 men scheduled to undergo the PAE procedure at UNC Hospital for benign prostatic hyperplasia. Procedures (methods): Study subjects will undergo PAE using the standard technique. Prior to embolization of the prostatic artery with the bland embolic agent, Ga-68 MAA will be injected. Standard departmental radiation protection procedures will be followed. After the PAE procedure is complete, the patient will be transported to the UNC Biomedical Research Imaging Center to undergo PET/MRI.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
BTG International Inc.
Embolx, Inc.